Most tirzepatide vs semaglutide explainers skip the one thing that matters: there is only one large trial that put them against each other. In that study, tirzepatide produced more average weight loss over 72 weeks. But the two drugs work through different receptors, most published trials tested each on its own, and the difference on paper says little about how a single person will respond. The useful comparison is narrower and more honest than the marketing suggests.
Are these even the same kind of drug?
They are relatives, not twins. Semaglutide targets the GLP-1 receptor, the pathway behind the appetite and blood-sugar effects people associate with this class. Tirzepatide acts on two receptors, GIP and GLP-1, which is why it is called a dual agonist. The theory is that adding GIP activity changes how the body handles food intake and fat storage, and the weight-loss numbers are consistent with something extra happening. Whether that mechanism fully explains the gap is not settled.
Both are given as once-weekly injections and both are titrated slowly. The prescribing information for the tirzepatide brands, Zepbound and Mounjaro, lays out that stepwise increase, and semaglutide follows a similar pattern. The slow ramp exists to reduce nausea, not to slow-walk results, though it does mean the first months rarely show the headline figures.
What did the one direct trial actually find?
In 2024, a randomized trial published in a major journal compared tirzepatide and semaglutide directly in adults with overweight or obesity, and it reported greater average weight loss with tirzepatide over the study period. That is the closest thing to a fair fight in the literature, and it favored tirzepatide.
Two cautions keep that from being the last word. It is one study, and averages hide enormous individual spread: some people on semaglutide out-lose the tirzepatide average, and some on tirzepatide barely respond. And most of what we know comes from separate programs. Tirzepatide’s obesity evidence sits in the SURMOUNT-1 trial and its extensions, while semaglutide’s comes from the STEP program. Comparing a number from one against a number from the other is the mistake nearly every casual comparison makes.
How do they line up on the things people actually ask?
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor target | GLP-1 | GIP and GLP-1 |
| Dosing | Weekly injection, titrated | Weekly injection, titrated |
| Head-to-head weight loss | Lower average in the 2024 trial | Higher average in the 2024 trial |
| Main side effects | Nausea, diarrhea, constipation | Nausea, diarrhea, constipation |
| Regain after stopping | Documented in STEP 4 | Documented in SURMOUNT-4 |
Do the side effects really differ?
Less than people expect. Both are dominated by gastrointestinal effects, and both are worst while the dose is climbing. The direct comparison did not reveal a wildly different safety profile between them. The semaglutide STEP program, including the STEP 8 trial that compared it against daily liraglutide, showed the same familiar pattern of nausea and digestive complaints that fade for many as the dose stabilizes.
The honest takeaway is that side-effect tolerance is individual. Some people sail through tirzepatide and stall on semaglutide, or the reverse. Choosing based on a generic side-effect ranking is guessing.
What does the evidence say about specific conditions?
The tirzepatide program has pushed into territory beyond weight alone. A dedicated trial studied tirzepatide in obstructive sleep apnea alongside obesity, and the SURMOUNT-CN trial tested it in Chinese adults with obesity, showing the effect is not limited to the populations in the original studies. This does not make tirzepatide automatically better for everyone; it means its evidence base has widened into areas semaglutide’s obesity trials have not all covered.
What happens when someone stops?
This is the part worth being blunt about. Both drugs behave like ongoing treatments, not cures. The STEP 4 trial showed that people who stopped semaglutide regained much of what they had lost, and the SURMOUNT-4 trial found the same pattern with tirzepatide: continued treatment maintained the loss, withdrawal reversed a large share of it. Choosing between the two without a plan for the long run misses the more important decision.
How does cost and access change the comparison?
The molecule debate collapses fast once price enters. Both are expensive, and what a person pays depends on whether a plan covers weight management, whether a manufacturer savings card applies, and what the cash routes cost. Brand programs such as LillyDirect and NovoCare, and telehealth services including Ro, Hims and Hers, and Henry Meds, each price differently, and some patients compare a supervised compounded option like FormBlends against the brand self-pay figure before deciding. Compounded tirzepatide and semaglutide are prepared by compounding pharmacies and are not FDA-approved products, which is a genuine difference from the brands, not a footnote. For someone paying cash, the accessible drug can beat the theoretically stronger one that they cannot sustain.
So which should someone pick?
If the only thing on the table is expected average weight loss and both are equally affordable and tolerable, the direct trial points toward tirzepatide. That is a narrow if. Semaglutide has the longer real-world track record, both address the same underlying goal, and tolerance and cost decide more cases than the head-to-head number does. Picking the drug you can actually stay on beats picking the one that won a single trial and then stopping it in four months.
Key takeaways
- Only one large trial compared them directly, and it favored tirzepatide on average.
- Semaglutide is a GLP-1 drug; tirzepatide adds GIP activity as a dual agonist.
- Side-effect profiles overlap heavily and are worst during dose increases.
- Both regain weight after stopping, so the long-term plan matters more than the pick.
- Cost, coverage, and tolerance usually decide the real-world choice.
See also: Time Attendance Systems in Dubai: What Businesses Need to Know in 2026
Frequently asked questions
Which one causes more weight loss?
In the one large trial that compared them directly, tirzepatide produced greater average weight loss than semaglutide over 72 weeks. That is a real result, but it is a single study in people with overweight or obesity, and individual response varies widely.
Are they the same kind of drug?
Not quite. Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both the GIP and GLP-1 receptors, which is why it is described as a dual agonist rather than a straight GLP-1 medicine.
Do the side effects differ much?
Both are dominated by gastrointestinal effects such as nausea, diarrhea, and constipation, and both are worst during dose increases. The direct comparison trial did not show a dramatically different safety profile between them.
What happens if I stop taking either one?
Trials of both drugs show that stopping is followed by regain of a large share of the lost weight. Maintenance studies treated these as long-term medicines, not short courses.
Is compounded tirzepatide or semaglutide the same as the brand?
No. Compounded versions are prepared by compounding pharmacies and are not FDA-approved products. They may use the same active molecule, but they have not gone through the approval process that produced the trial evidence.
